Pharma joint ventures

DSM’s former Pharma Cluster comprised the business group DSM Pharmaceutical Products, one of the world’s leading custom manufacturing organizations to the pharmaceutical industry, and DSM's 50% joint venture interest in DSM Sinochem Pharmaceuticals, leader in beta-lactam anti-infectives.

Leveraging partnerships for growth

In 2013, DSM completed the third year of its successful strategy DSM in motion: driving focused growth, which it launched in 2010 to become a global leader in health, nutrition and materials. The strategy’s objective for our Pharma Cluster was Leveraging partnerships for growth.

DSM Sinochem Pharmaceuticals

DSM Sinochem Pharmaceuticals

In August 2011 DSM announced that it had established the 50/50 global joint venture for its business group DSM Anti-Infectives with the Sinochem Group, DSM Sinochem Pharmaceuticals.



In March 2014 DSM and JLL Partners (JLL), the middle-market private equity firm, announced that DPx Holdings B.V. (DPx) was operational.

DPx, formed by combining DSM Pharmaceutical Products and Patheon Inc., is a leading global contract development and manufacturing organization (CDMO) for the pharmaceutical industry with anticipated sales of around USD 2 billion, a strong EBITDA and operational cash flow and more than 8,000 employees. DPx is 51% owned by JLL and 49% by Royal DSM.

Cluster strategy concluded

With the announcement on 11 March 2014 that DPx was operational, DSM concluded its strategic objectives of Leveraging partnerships for growth for its Pharma cluster.

Equity method

Accordingly, as of 1 January 2014 the Pharma cluster is no longer included in DSM’s core EBITDA or activities and DSM will report on its investments in joint ventures as an associated account in accordance with the equity method rather than as ongoing business.


You have requested the following file:

Choose an option: